PPD, Inc.

Christine Dingivan, M.D. has been appointed executive vice president and chief medical officer, PPD, Inc. Dr. Dingivan provides strategic direction for global regulatory affairs and pharmacovigilance, biomarker discovery sciences, Phase I, and bioanalytical and cGMP lab services. She is also responsible for medical assessment of clinical data as well as adherence to ethical standards and good lab practices.
   
Prior to joining the company, Dr. Dingivan spent 12 years with MedImmune, which was acquired by AstraZeneca in 2007. She most recently served as senior vice president of clinical development and operations, having previously held a number of roles with increasing responsibility. She oversaw strategic development and implementation of global clinical research programs across all therapeutic areas, provided senior clinical leadership for U.S. and European regulatory applications, and chaired the clinical safety monitoring committee.
   
“Exceptional scientific, leadership and communications skills define Christine Dingivan,” said Fred Eshelman, chief executive officer of PPD. “With her in-depth experience in clinical development, strategic operations and medical affairs gained during her long tenure with MedImmune, she will play a key role in helping us advance our clients’ products through development. I am pleased to welcome her to PPD.”